Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways

Basit Öğe Kaydı
dc.contributor.authorOzler, Serkan
dc.contributor.authorPazarci, Percin
dc.date.accessioned2024-09-18T20:02:34Z
dc.date.available2024-09-18T20:02:34Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe incidence of prostate cancer in the world is increasing every year. Death caused by prostate cancer is increased by 13% in men between 1980 and 2005. It is the second leading cause of cancer death in men after lung cancer. Bladder cancer is the second most common of urological malignancies. Most of the bladder cancers are treated with transurethral resection. Even great efforts have been made in the treatment of bladder cancer over the past years, it still remains as a major health problem. New therapeutic approaches are required to prevent the development and metastasis of these diseases. Experimental and clinical studies have shown potential beneficial effects of co-administration of beta-adrenergic receptor antagonists (beta-blockers) during cancer therapy. This study aimed to investigate the anti-tumor activity of beta-blockers on prostate and bladder cancer. Prostate and bladder cancer cell lines were cultured and treated with beta-blocker (propranolol). Then, protein levels and activity of apoptotic pathway mediators and mitogen-activated protein kinase (MAPK) pathway mediators were analyzed by ELISA. Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein. Propranolol treatment also inhibited ERK and JNK activity. This study showed that propranolol will help to inhibit prostate and bladder cancer by activating apoptotic pathway and by inhibiting MAPK pathway. This is the first study investigating the apoptotic effect of propranolol via MAPK on prostate and bladder cancer.en_US
dc.identifier.doi10.1097/CAD.0000000000001271
dc.identifier.endpage388en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue4en_US
dc.identifier.pmid35266887en_US
dc.identifier.scopus2-s2.0-85126388956en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage384en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001271
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7865
dc.identifier.volume33en_US
dc.identifier.wosWOS:000766755300006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectapoptosisen_US
dc.subjectbladder canceren_US
dc.subjectmitogen-activated protein kinaseen_US
dc.subjectpropranololen_US
dc.subjectprostate canceren_US
dc.titleAnti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathwaysen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
7865.pdf
Boyut:
667.03 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu